Epic Sciences Unveils DefineMBC™, A Novel Blood-Based Test Designed To Improve Care For Metastatic Breast Cancer Patients
Epic Sciences, Inc. announces DefineMBC, a novel metastatic breast cancer (MBC) test that includes both cell-based and cell-free analysis from a single blood draw. DefineMBC provides comprehensive MBC profiling when a tissue biopsy result is not available. Read Full Release
Epic Sciences Platform Demonstrates Compelling Value of Cell Analysis in Data Presented At San Antonio Breast Cancer Symposium 2021
Epic Sciences, Inc. (Epic)’s comprehensive liquid-biopsy platform continues to deliver compelling cancer profiling information as data presented during the San Antonio Breast Cancer Symposium 2021 demonstrate. Read Full Release
Epic Sciences Expands Leadership Team to Address Liquid Biopsy Demand
Epic Sciences, Inc., developer of novel diagnostics to personalize and advance the treatment and management of cancer, today announced the appointment of Jason Christiansen as Chief Technology Officer, Mark Aguillard as Vice President/ General Manager of the Oncology Business Unit, and Amara Siva as Vice President of Laboratory Operations. These three new executives bring a combined 60 plus years of experience to the Epic Sciences team. Read Full Release
Epic Sciences Comprehensive Cancer Profiling Platfom Shows Compelling Value of Cell Analysis in Data Presented At ESMO Congress 2021
Epic Sciences, Inc.'s (Epic) Comprehensive Cancer Profiling™ Platform continues to deliver compelling cell analysis information in clinical trials as data being presented today at the virtual European Society for Medical Oncology Congress 2021 (ESMO 2021) demonstrate. Read Full Release


01.18.2022 | ZEISS
Looking for One in Many Millions
Circulating tumor cells (CTCs) are cells that have broken away from a primary tumor and entered the circulatory system. They can initiate new tumors (metastases) that are the driving factor for the vast majority of cancer-related deaths. Biopharma researchers, cancer researchers and oncologists have focused on the detection and analyses of CTCs to monitor drug responses and determine appropriate treatments. Read Full Article
05.02.2021 | Clinical OMICs
Shifting Paradigms in Precision Oncology
Epic Science’s core proprietary technology involves single-cell sequencing of circulating tumor cells (CTCs), but it uses ctDNA and white blood cells derived from a single blood draw in its work. Read Full Article
11.30.2020 | genomeweb
Epic Sciences, USC Michelson Center Sign Licensing Agreement for Liquid Biopsy Research

NEW YORK – Epic Sciences said on Thursday that it has signed a licensing agreement with the University of Southern California's Michelson Center for Convergent Bioscience to improve the firm's liquid biopsy platform and allow for more precise characterization of rare circulating tumor cells (CTCs).

As part of the collaboration, San Diego-based Epic will have access to the center's liquid biopsy samples and expand its platform to in-depth characterization of both cell-free fractions and CTCs using genomic, proteomic, and AI-based morphological tools. Read Full Article

11.09.2020 | Clinical OMICs
Companies are rapidly advancing liquid biopsies as the go-to technology for cancer treatment monitoring and recurrence
Liquid biopsies are becoming increasingly sensitive and personal thanks to advances in next-generation sequencing and target amplification. In addition, machine learning algorithms are being used on large datasets to characterize the molecular signatures of various cancer types. Read Full Article


ISLB 2020
The Epic Sciences team presented at the virtual ISLB 2020 Annual Congress Meeting - October 30, 2020. More Info
ASCO 2020
The Epic Sciences team will be presenting at the virtual ASCO 2020 Annual Meeting - From May 29 - 31, 2020. More Info
SABCS 2019
The Epic Sciences team will be attending and exhibiting at the San Antonio Breast Cancer Symposium - Booth #626 - in San Antonio, TX from December 10 - December 14, 2019. More Info
ASCO 2019
The Epic Sciences team will be attending ASCO 2019 Annual Meeting - Booth #2066 - in Chicago, IL from May 31 - June 4, 2019. More Info